Viva Ventures in the News

At Viva Ventures, we enjoy being part of innovative teams that are helping to change the world. 

 

Please take a look at some of our partners and projects. 

 

Most Recent

October, 2018

EndPoints News

SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer’s lab

In this new deal Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development goal money. Another $250 million is on the line for each new therapy that manages to make it all the way to an approval.

Read the article

 

July, 2018

 

Viva Biotech

August, 2018

EndPoints News

Merck hands Sutro $60M to start on immunomodulatory drug discovery; Eli Lilly spinning out animal health group

China’s Viva Biotech Holdings has applied for an IPO in Hong Kong to both fund their pursuit of promising upstarts and boost their manufacturing capabilities. 

Read the article

 

August, 2018

WhaTech

Protein expression market estimated to reach US$ 1654 million by 2022

Viva Biotech is among key players operating in the protein expression market.

Read the article

 

August, 2018

EndPoints News

Summing Up: Inside the Big Drug Discovery Service Industry | Healthcare 2018

Viva Biotech is a Key Player in the Drug Discovery Service Market

Read the article

 

Our Scientific Partners*

July, 2018

Pharmaceutical Business Review

 

*This is only a small selection of recent publications

 

Portfolio Companies

USEFUL LINKS

 

     JMCR Partners

 

     Sprout BioVentures

 

     Viva Biotech 

SITE NAVIGATION

 

     Home

 

     About Us

 

     Strategy

 

     Track Record

     Our Team

 

     Contact Us

  • Black Facebook Icon
  • Black LinkedIn Icon

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Viva Ventures Biotech Fund or any of our affiliates. Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Viva Ventures Biotech has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Viva Ventures biotech were prepared based upon information, believed to be reliable, available to it at the time such views were written. Viva Ventures Biotech makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Viva Ventures Biotech.